During Friday’s Morning trade, Shares of Tower stream Corporation (NASDAQ:TWER), lost -5.17% to $0.550.
Towerstream Corporation, declared results for the third quarter ended September 30, 2015 and offered a business update.
Operating Highlights and Business Update
Shared Wireless Infrastructure
- Executed small cell contracts with Verizon Wireless for the colocation of small cell equipment on shared wireless infrastructure.
- Revenues for the three months ended September 30, 2015 raised 7% contrast to the three months ended September 30, 2014.
- Syscom and HetNets declare landmark agreement to enable carriers to deploy wireless infrastructure on 45,000 Syscom billboards.
Fixed Wireless
- Tower stream connected 55 buildings with 15.8 million square feet and 1,527 possible customers to its On Net service of 100 MB of bandwidth for $699.
- Wholesale platform continues to grow with additional connections offered to existing CLEC customer and trial program launched with third CLEC.
- New sales center staffed and closing customer contracts ahead of internal plan.
Tower stream Corporation, together with its auxiliaries, provides various wireless communication services to commercial customers in the United States. It operates through two segments, Fixed Wireless and Shared Wireless Infrastructure.
Shares of Inter Cloud Systems Inc (NASDAQ:ICLD), declined -5.40% to $1.41, during its current trading session.
InterCloud Systems, stated financial results for the third quarter of 2015.
3rd Quarter and 9 Months Financial Highlights:
- Gross Profit for Q3 jumps 33% year-over-year to $7.2 million
- Revenue for Q3 raised 5% year-over-year to $21.7 million
- Adjusted EBITDA of $697 thousand contrast to a loss of $(1.5) million for the third quarter of 2014
- Gross Profit Margin of cloud segment was 82% for the quarter
- Gross Profit Margin at 33% for the 9 months contrast to 29% in 2014
Mark Munro, Chairman and CEO of Inter Cloud, stated, “We are very happy to report that year to date, Inter Cloud’s revenue has grown 25% over the same period in 2014. In addition to revenue growth, and equally important, we have raised our year to date gross profit margins to over 33% from 29% for the same period in 2014. Our aim is to continue to grow our business and focus on expanding our gross margins as we sell higher margin cloud services. InterCloud has some exciting new cloud products and services that will assist us achieve those aims. Our near term and long term outlook is very positive and we look forward to ramping up our portfolio of recurring revenue. Inter Cloud is positioned competitively with a robust private cloud portfolio of services, an industry leading software development team, and an aggressive sales and engineering group that will ultimately assist us achieve our aims and objectives of being a market leader in cloud networking orchestration and automation solutions to enterprise and service provider markets.”
InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally. It operates through three segments: Applications and Infrastructure, Professional Services, and Cloud and Managed Services.
Finally, Shares of Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI), gained 1.33%, and is now trading at $0.760.
Rock Creek Pharmaceuticals, declared its third quarter results. The Company also revealed the Notification of Intent to Grant by the European Patent Office of a European patent for the administration of Anatabine to treat autism spectrum and seizure disorders.
Autism Spectrum Disorders
Autism spectrum disorders (ASDs) are pervasive neurodevelopmental disorders diagnosed in early childhood when attained skills are lost or the acquisition of new skills become delayed. ASDs onset in early childhood and are associated with varying degrees of dysfunctional communication and social skills, in addition to repetitive and stereotypic behaviors. In many cases (25%-50%), a period of seemingly normal development drastically shifts directions as attained skills are lost or the acquisition of new skills becomes delayed. Examples of ASDs comprise “classical” autism, Asperger’s syndrome, Rett syndrome and other pervasive developmental disorders.
Previous research has suggested that there is excess inflammation in the colon, esophagus and duodenum of some patients with autism and postmortem studies have also shown an improvement in the expression of several markers of neuro-inflammation. There is also evidence that nicotinic acetylcholine receptor (nAChR) agonists, especially those that target the alpha-7 subtype, may be useful in treating ASD. For instance, it has been suggested that activating the alpha-7 nAChR may provide symptomatic relief in ASD by reducing chronic inflammation and providing pro-cognitive effects. Anatabine has been shown in a variety of preclinical models to activate alpha-7 nAChRs, reduce inflammation in several animal models and to normalize social behavior in transgenic models of Alzheimer’s disease.
As formerly revealed, the Company believes that isolated forms of Anatabine could be particularly useful for treating diseases or disorders with an inflammatory component characterized by excessive NF-kB mediated transcription. Although the Company is focusing its resources and clinical development program on dermatological diseases, the Company is communicating with the scientific and medical community for potential collaborative and independent, investigative study for autism spectrum and related disorders.
Rock Creek Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health.